Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 109, Issue 6, Pages 893-899Publisher
WILEY
DOI: 10.1002/ijc.20050
Keywords
glioma; innate immunity; interferon-gamma; immunotherapy; CD1d
Categories
Funding
- NCI NIH HHS [CA 84512] Funding Source: Medline
- NCRR NIH HHS [M01 RR-00102] Funding Source: Medline
Ask authors/readers for more resources
Brain tumors carry a poor prognosis, and newer approaches to their therapy are urgently needed. Natural killer T (NKT) cells are distinct innate lymphocytes with antitumor potentials. Defects in NKT cell function have been observed in patients with other forms of cancer. Here we show that both the frequency and interferon-gamma-producing function of NKT cells are well preserved in adult patients with glioma (n = 9) and comparable to findings in healthy controls (n = 9). These cells can be readily expanded in culture using autologous mature dendritic cells loaded with the NKT ligand, a-galactosyl ceramide. The expanded NKT cells from glioma patients are functional and, importantly, kill glioma cells in a ligand- and CD1d-dependent manner. Expression of CD1dd is detected both on primary glioma cells as well as endothelial Fells in infiltrating new blood vessels by immunohistochemistry of glioma tissue sections. These data suggest that targeting NKT cells may provide a novel strategy for immunotherapy of glioma. (C) 2004 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available